Tag Archives: NUVA

Analysts’ Perspective: Edwards Lifesciences (EW), GP Strategies (GPX), NuVasive (NUVA)

Investment Analysts at Barclays upgraded Edwards Lifesciences Corp. (NYSE:EW) shares from Equal Weight to Overweight rating while increasing their price target of $125 to $135.

Edwards Lifesciences Corp. engages in the design, development, manufacture, and markets products to treat stage cardiovascular disease.

*

GP Strategies Corp. (NYSE:GPX) shares were upgraded by analysts at B. Riley FBR, Inc. Bank from Neutral to Buy rating while increasing there price target of $24.50 to $28.

GP Strategies Corp. provides training, e-Learning solutions, management consulting and engineering services.

*

Brokerage Firm Needham upgraded NuVasive Inc. (NASDAQ:NUVA) shares from Underperform to Buy rating with a price target of $71.

NuVasive, Inc. is medical device company, which engages in the development of minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery.

**

Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWE.Info is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://www.crwe.info/disclaimer/